PBYI — Puma Biotechnology Cashflow Statement
0.000.00%
Last trade - 00:00- $148.83m
- $114.92m
- $230.47m
- 77
- 96
- 88
- 99
Annual cashflow statement for Puma Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -60 | -29.1 | 0.002 | 21.6 | 30.3 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 37.6 | 39.8 | 18.8 | 11.8 | 7.73 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 13.2 | -0.602 | -43.6 | -17.9 | -3.54 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | 0.773 | 20.6 | -15.8 | 27 | 38.9 |
| Capital Expenditures | -20 | 0 | -7 | -12.6 | -0.056 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 43.4 | -10.9 | 14.1 | -6.49 | -20.4 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 23.4 | -10.9 | 7.1 | -19.1 | -20.4 |
| Financing Cash Flow Items | 0 | -30.4 | 0 | 0 | -0.666 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.068 | -31.9 | 12.2 | 0 | -33.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 24.2 | -22.2 | 3.5 | 7.88 | -15.4 |